Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

Similar articles for PubMed (Select 23328938)

1.

Tapentadol extended release for chronic pain patients.

Taylor R, Pergolizzi JV, Raffa RB.

Adv Ther. 2013 Jan;30(1):14-27. doi: 10.1007/s12325-013-0002-y. Epub 2013 Jan 15. Review.

PMID:
23328938
2.

Efficacy of tapentadol ER for managing moderate to severe chronic pain.

Afilalo M, Morlion B.

Pain Physician. 2013 Jan;16(1):27-40. Review.

3.

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.

Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J.

Clin Drug Investig. 2010;30(8):489-505. doi: 10.2165/11533440-000000000-00000.

PMID:
20586515
4.

Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.

Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH.

Clin Ther. 2013 May;35(5):659-72. doi: 10.1016/j.clinthera.2013.03.016. Epub 2013 Apr 13.

PMID:
23587608
5.

Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain.

Coluzzi F, Ruggeri M.

Curr Med Res Opin. 2014 Jun;30(6):1139-51. doi: 10.1185/03007995.2014.894501. Epub 2014 Mar 3.

PMID:
24528146
6.

Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T.

Clin Drug Investig. 2014 Jul;34(7):501-11. doi: 10.1007/s40261-014-0204-3.

7.

Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.

Neil N, Merchant S, Provenzano D, Ogden K, Mody SH.

J Med Econ. 2013;16(2):307-17. doi: 10.3111/13696998.2012.756401. Epub 2012 Dec 14.

PMID:
23216013
8.

Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.

Steigerwald I, Schenk M, Lahne U, Gebuhr P, Falke D, Hoggart B.

Clin Drug Investig. 2013 Sep;33(9):607-19. doi: 10.1007/s40261-013-0102-0.

9.

Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.

Gálvez R, Schäfer M, Hans G, Falke D, Steigerwald I.

Adv Ther. 2013 Mar;30(3):229-59. doi: 10.1007/s12325-013-0015-6. Epub 2013 Mar 7.

PMID:
23475406
10.

A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain.

Etropolski M, Lange B, Goldberg J, Steup A, Rauschkolb C.

J Opioid Manag. 2013 Sep-Oct;9(5):343-56. doi: 10.5055/jom.2013.0177.

PMID:
24353047
11.

Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.

Kress HG, Koch ED, Kosturski H, Steup A, Karcher K, Lange B, Dogan C, Etropolski MS, Eerdekens M.

Pain Physician. 2014 Jul-Aug;17(4):329-43.

12.

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.

Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M.

Expert Opin Pharmacother. 2010 Aug;11(11):1787-804. doi: 10.1517/14656566.2010.497720. Erratum in: Expert Opin Pharmacother. 2010 Nov;11(16):2773.

PMID:
20578811
13.

Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.

Ikenberg R, Hertel N, Moore RA, Obradovic M, Baxter G, Conway P, Liedgens H.

J Med Econ. 2012;15(4):724-36. doi: 10.3111/13696998.2012.670174. Epub 2012 Mar 28. Erratum in: J Med Econ. 2012;15(6):1216.

PMID:
22364286
14.

Tapentadol extended release: in adults with chronic pain.

Hoy SM.

Drugs. 2012 Feb 12;72(3):375-93. doi: 10.2165/11208600-000000000-00000. Review.

PMID:
22316353
15.

Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain.

Imanaka K, Tominaga Y, Etropolski M, van Hove I, Ohsaka M, Wanibe M, Hirose K, Matsumura T.

Curr Med Res Opin. 2013 Oct;29(10):1399-409. doi: 10.1185/03007995.2013.831816. Epub 2013 Aug 23.

PMID:
23937387
16.

[Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].

Schwittay A, Schumann C, Litzenburger BC, Schwenke K.

MMW Fortschr Med. 2012 Oct 4;154 Suppl 3:85-93. German.

PMID:
23133884
17.

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.

Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, Rauschkolb C.

Curr Med Res Opin. 2011 Jan;27(1):151-62. doi: 10.1185/03007995.2010.537589.

PMID:
21162697
18.

Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.

Merchant S, Provenzano D, Mody S, Ho KF, Etropolski M.

J Opioid Manag. 2013 Jan-Feb;9(1):51-61. doi: 10.5055/jom.2013.0147.

PMID:
23709304
19.

Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain.

Lerner D, Chang H, Rogers WH, Benson C, Chow W, Kim MS, Biondi D.

J Occup Environ Med. 2012 Aug;54(8):933-8. doi: 10.1097/JOM.0b013e31825f31a1.

PMID:
22850352
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk